Background & Aim Enabling stem cell-base therapies requires innovative solutions to close the gaps existing between research and commercialization. Allogeneic cell therapy indications that target large patient populations will necessitate the use of flexible cell production platforms to meet required cell quantities. Developing a truly scalable, controlled bioreactor platforms for cell expansion enables meeting cell quantity demand for clinical applications while allowing comparability between the various scales. Likewise, it enhances process automation and allows integration of online monitoring systems. The capability of effectively culturing adherent stem cells, namely pluripotent stem cells, will be presented. Methods, Results & Conclusion Our platform take advantage of 3D, stirred tank bioreactors, expanding hPSCs in suspension. Our data shows that hPSCs expand rapidly and efficiently in a 3L bioreactor, while retaining normal karyotyping and hPSC-associated characteristics. hPSCs are fed with an animal-free hPSC media, perfused into a closed, monitored and controlled, bioreactor, with no need for cell passaging. The platform supports expansion of hPSCs seeded in a bioreactor either when harvested from 2D cell culture or when thawed directly into the suspension vessel. Thawing cryopreserved cells directly into a suspension vessel eliminates the need for a 2D seed train and, therefore, greatly reduces labor, time and contributes to process aseptic, monitoring and automation. Furthermore, we show that 3D seed train from one suspension vessel to another is a feasible and viable solution for large-scale expansion of hPSCs. hPSCs expanded in a bioreactor are shown to have the capability to be directly differentiated in suspension. This expansion platform and associated attributes provides end-to-end, cryo-to-cryo solution for hPSC manufacturing. Expanding hPSCs in suspension, in a controlled bioreactor, results in high fold expansion without compromising cell quality, and the capacity of the cells to be further differentiated. This platform avoids 2D cell culture steps, reduces footprint, labor and cost, while enhancing process control and cell product quality.